Bormioli Pharma Keeps on Innovating on Glass to Achieve a Better Performing & More Sustainable Product

As the celebrations for the International Year of Glass are currently underway in Geneva, Switzerland, Bormioli Pharma recently announced new research and innovation projects. Through a series of initiatives carried out with an Open Innovation approach, combining internal resources with Research Centres, Universities and start-ups, the company aims at developing better performing and more sustainable glass products.

In particular, the collaboration with IMEM-CNR – within a new Research Center dedicated to glass – is now underway to allow – through the funding of a 3-years PhD scholarship -, the development of new external and internal coatings able to increase the performance of glass, both from a chemical and mechanical point of view.

Performance-wise, the company is also experimenting – again as a result of a specific collaboration with the CNR – with an innovative treatment to make Type II (soda-lime) glass bottles even more resistant, thus ensuring greater stability of the pharmaceutical formulations they will contain.

About sustainability, Bormioli Pharma has recently joinedGlass Future, a UK-based project that aims to develop an innovative, low CO₂ emission approach to glass production. The project, which will last ten years, will soon see the opening of a pilot furnace in the UK dedicated to the experimentation and application of these technologies.

“In a celebration year for glass, we are ready to confirm our role as innovators in the industry, with several concrete research and development initiatives,” said Andrea Lodetti, CEO of Bormioli Pharma. “This commitment is all the more important in a sector such as pharmaceuticals, where glass must not only contain, but also protect the therapeutic efficacy, and where the constant increase in production requires a serious rethinking of our responsibilities towards the environment.”

Sustainability is a key pillar for Bormioli Pharma, which has committed to manufacturing 50% of its products using materials with low environmental impact by 2025. The company will also publish its first Integrated Report based on ESG parameters by H1 2022.

Bormioli Pharma works closely with the pharmaceutical industry and all companies that are working toward the future of healthcare globally. As a world-renowned player in the packaging industry, the company serves the pharmaceutical and biopharmaceutical market with complete solutions, including glass and plastic bottles, plastic and aluminum closures and accessories. Each product is a unique combination of rigorous studies, cutting-edge technologies, advanced testing, industrial processes and premium materials. Bormioli Pharma has a global presence in more than 100 countries, with more than 1,300 employees and 10 plants in Europe specializing in the production of glass and plastic packaging. Each year the company produces more than 7 billion items, and in 2020 it recorded annual sales of approximately 260 million euros. As a partner to the pharmaceutical industry, Bormioli Pharma invests and innovates with one goal in mind: to improve people’s lives.